An independent source of information on U.S. brand name drugs for health professionals

Drugdocs Logo

An independent source of information on U.S. brand name drugs for health professionals

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Verquvo

Chemical Namevericiguat
Dosage FormTablet (oral; 2.5mg, 5mg,10mg)
Drug ClassMiscellaneous
SystemCardiovascular
CompanyMerck & Co.
Approval Year2021

Indication

  • To reduce the risk of cardiovascular death and heart failure (HF) hospitalization following a hospitalization for heart failure
  • To reduce the need for outpatient IV diuretics, in adults with symptomatic chronic HF and ejection fraction less than 45%
Last updated on 1/28/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Verquvo (vericiguat) Prescribing Information2021Merck Sharp and Dohme Corp., Whitehouse Station, NJ
Document TitleYearSource
Relative efficacy of sacubitril-valsartan, vericiguat, and SGLT2 inhibitors in heart failure with reduced ejection fraction: a systematic review and network meta-analysis.2020Cardiovascular Drugs and Therapy
Safety and efficacy of soluble guanylate cyclase stimulators in patients with heart failure: A systematic review and meta-analysis.2020World Journal of Cardiology
The efficacy and safety of soluble guanylate cyclase stimulators in patients with heart failure: A systematic review and meta-analysis.2018Medicine (Baltimore)